tpi 287



Glioblastoma (GBM) is the most aggressive and common form of brain cancer. The Central Brain Tumor Registry estimates that about 23,830 primary malignant brain tumors cases will be diagnosed in the US in 2018, 46% of which will be primary GBM. Typical front-line treatments include stereotactic or whole brain radiotherapy plus temozolomide (Temodar®). Patients with recurrent disease are candidates for treatment with Avastin®, the last FDA approved agent for this disease.

Given the unique properties of TPI 287 as a brain penetrable taxane, we are evaluating this agent in combination with Avastin in the following multi-center clinical trial:

  • CB-017: A Phase 1/2 trial evaluating the combination of Avastin plus TPI 287 for treatment of patients with recurrent GBM who have not received prior Avastin for treatment of their disease ( NCT01933815)

Secondary brain metastases

Approximately 150,000 – 200,000 patients with primary tumors originating outside of the brain are diagnosed with secondary brain metastases every year. Radiation therapy is the only approved regimen for treatment of brain lesions. Cortice collaborators are evaluating TPI 287 for the treatment of brain metastases in two clinical trials:

  • An open-label study of TPI 287 monotherapy in patients with breast cancer metastatic to the brain ( NCT01332630)
  • An open-label study of TPI 287 plus fractionated stereotactic radiation therapy (FSRT) for treatment of patients with lung or breast cancer that has metastasized to the brain ( NCT02187822)